Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > BUSINESS
BUSINESS
- Chugai Drops Five Early-Stage Programs to Refocus Pipeline
July 25, 2025
- Pfizer Japan Recalls Syphilis Drug over Particulate Contamination
July 25, 2025
- Chugai Delivers Positive H1 Earnings on Innovative Drugs, Export Growth
July 25, 2025
- IQVIA, JFCR Cancer Institute Partner to Speed Clinical Trials in Japan
July 25, 2025
- FRONTEO’s AI Engine Uncovers Novel Pancreatic Cancer Targets as Company Eyes Out-Licensing
July 24, 2025
- Eisai Launches Beova in Thailand with Rights Obtained from Kyorin
July 24, 2025
- Towa Launches Task Force to Tackle Nitrosamine Impurities, Share Solutions with Peers
July 24, 2025
- Alloy Japan Teams with KSAC to Back University Startups’ Global Push
July 23, 2025
- FDA Panel Rejects Rexulti’s PTSD Bid: Otsuka/Lundbeck
July 23, 2025
- Santen’s Myopia Drug Ryjunea Now Available in Germany
July 23, 2025
- Moderna Drops Plan for mRNA API Site in Japan as Vaccine Demand Slumps
July 22, 2025
- Sanofi to Take Over Japan MA for Beyfortus from AstraZeneca
July 22, 2025
- Multi-Dose Wegovy Pen Now Available in Japan: Novo
July 22, 2025
- Enhertu Combo Gets Breakthrough Tag for First-Line HER2 Breast Cancer
July 22, 2025
- Nippon Chemiphar Signs On to Meiji-Daito Consortium as Talks Accelerate
July 22, 2025
- Ex-Finance Official Says Treating Obesity Could Lower Japan’s Healthcare Costs
July 22, 2025
- JRI Urges Reforms in Pricing and Reimbursement to Support Regenerative Medicine Ecosystem
July 18, 2025
- Astellas Partners with KISED to Support Korean Biotech Startups
July 18, 2025
- Kowa Picks Up Global Rights to Nicox’s Glaucoma Drug Excluding Asia
July 18, 2025
- Alnylam’s Amvuttra Could Become First-Line Therapy for ATTR-CM, Says Expert
July 18, 2025
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…